*This form should be completed by outline applicants for the Experimental Medicine funding scheme, with reference to the Guidance for Outline Stage Applicants.*

*Use the tab key to move between cells in the form. Cells that are greyed out do not need to be filled in, since these are automatically calculated from cells elsewhere in the form. To ensure that all the automatic calculations are undertaken, please start from the first entry and tab through the entire document; alternatively, press F9 to update all fields.*

*When completed, this form must be converted to a PDF file and submitted via the Joint electronic Submission (Je-S) system as part of an Outline Application for Experimental Medicine funding as an attachment under document type “Case for Support”.*

*Version 1.0*

*June 2020*

Section 1: Project Summary

|  |
| --- |
| **1.1 Title (max 150 characters) [same as Je-S Project Title]** |
|  |

|  |
| --- |
| **1.2 Technical Summary (max 2000 characters) [same as Je-S Technical Summary]** |
|  |

|  |  |
| --- | --- |
| **1.3 Project Duration and Cost [same as in Je-S submission]** | |
| **Proposed start date**  **(dd.mm.yyyy)** |  |
| **Proposed duration of award**  **(Months)** | 0 |
| **Project fEC**  **(£000s)** | 0 |
| **Estimated MRC Contribution @ 80% fEC (£000s)** | 0 |
| **Project Partner Contribution**  **(£000s)** | 0 |

Section 2: Investigator Details

Please also refer to Section 1.3 of the [MRC Guidance for Applicants](https://mrc.ukri.org/funding/guidance-for-applicants/1-who-can-apply-and-how-to-apply/#1.3) for definitions and further information.

|  |  |
| --- | --- |
| **2.1 Principal Investigator [same as Je-S Principal Investigator]** | |
| **Name** |  |
| **Post Held** |  |
| **Department** |  |
| **Institution** |  |

|  |  |
| --- | --- |
| **2.2 Co-Investigators [same as Je-S Co-Investigators]** | |
| **Name** | **Institute / Organisation / Company** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |
| --- | --- |
| **2.3 Researcher Co-Investigators [same as Je-S Researcher Co-Investigators]** | |
| **Name** | **Institute / Organisation / Company** |
|  |  |
|  |  |
|  |  |

|  |  |
| --- | --- |
| **2.4 Industrial Project Partners [Project Partners in Je-S]** | |
| **Name** | **Institute / Organisation / Company** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |
| --- | --- |
| **2.5 Non-Industrial Project Partners (Collaborators) [Project Partners in Je-S]** | |
| **Name** | **Institute / Organisation / Company** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

|  |  |
| --- | --- |
| **2.6 Subcontractors** | |
| **Name** | **Institute / Organisation / Company** |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

Section 3: Background

|  |
| --- |
| **3.1 Please describe the objectives in terms of the gap in understanding of mechanisms and why this gap is important to address (max 200 words)** |
|  |

|  |
| --- |
| **3.2 Please summarise the current state of understanding about the relevant mechanisms of disease (max 200 words)** |
|  |

|  |
| --- |
| **3.3 Please provide relevant background information on the proposed tool (compound, biologic, psychological / physiological intervention, etc). Please briefly summarise the development history of the tool and its use in other mechanistic studies (max 200 words)** |
|  |

Section 4: Rationale

|  |
| --- |
| **4.1 What is the rationale and supporting evidence for your approach? (max 600 words)** |
|  |

|  |
| --- |
| **4.2 Please provide up to 5 relevant references (max 80 words)** |
|  |

Section 5: Research Plans

|  |
| --- |
| **5.1 How do you propose to address the identified gap in knowledge? Please detail any relevant pilot data, and highlight any innovative approaches, techniques or technologies that are likely to bring particular benefits. What is the nature of human participation in your research proposal? What type of subjects (e.g. age, disease) will be used? How will this approach complement studies conducted *in vitro* or in animal models *in vivo*? (max 800 words).** |
|  |

|  |
| --- |
| **5.2 In the future, where do you anticipate the findings having impact (i.e. is there a route to patient benefit, will results be valuable for discovery science through 'reverse translation')? (max 150 words)** |
|  |

Section 6: Deliverability

|  |
| --- |
| **6.1 How will the project achieve its objectives? Summarise the project workplan, including at least two key progression milestones (one being the project end). For each Milestone, please set out the success criteria that will be used, and detail robust Go / No-Go criteria (max 400 words)** |
|  |

|  |
| --- |
| **6.2 Identify and justify the skills and resources (materials, methods, data, people, infrastructure, outsourced tasks, etc.) needed to undertake the proposed project. Please specify the need, the costs and the timelines of usage / employment (max 300 words)** |
|  |

|  |
| --- |
| **6.3 How will the project be managed, and what experience does the team have of managing similar projects? (max 120 words)** |
|  |

|  |
| --- |
| **6.4 Will the proposal make use of existing infrastructure for Experimental Medicine (e.g. Experimental Cancer Medicine Centres, NIHR’s Biomedical Research Centres, patient cohorts, etc)? (max 120 words)** |
|  |

|  |
| --- |
| **6.5 Please list the key risks to delivering the project, how likely these are to occur, and what their impact would be on the success and deliverability of the project? How will these risks be managed, in particular regarding participant recruitment? (max 300 words)** |
|  |

|  |
| --- |
| **6.6 Please summarise the statistical analysis plan, identifying the primary and secondary endpoints and the proposed sample sizes, providing sufficient detail for replication of any power calculations. Consider potential sources of biases and describe strategies that will be adopted to minimise their effects (1 page)** |
|  |

Section 7: Intellectual Property

*Note that the generation of protectable intellectual property is not an essential requirement for this scheme.*

|  |
| --- |
| **7.1 Do the applicants have freedom to operate for this project? If access is required, what IP does the proposal need access to? (max 150 words)** |
|  |

|  |
| --- |
| **7.2 Is the project expected to produce any new IP or knowledge? (max 150 words)** |
|  |

|  |
| --- |
| **7.3 How will project generated IP be managed and exploited? Detail the organisations / individuals who will own any arising IP and any live, pending or envisioned agreements governing ownership or exploitation of that IP (max 150 words)** |
|  |

Section 8: Project Duration and Cost

|  |  |  |
| --- | --- | --- |
| **Step** | **Duration**  **(months)** | **fEC Cost**  **(£000s)** |
| **Milestone 1** | 0 | 0 |
| **Milestone 2** | 0 | 0 |
| **Milestone 3 [if applicable]** | 0 | 0 |
| **Milestone 4 [if applicable]** | 0 | 0 |
| **Entire Project fEC** | 0 | 0 |
| **Estimated MRC Contribution @ 80% fEC (same as Je-S total)** |  | 0 |
| **Project Partner Contribution** |  | 0 |

|  |
| --- |
| **8.1 If you have requested support for resources under Exceptions Costs, please describe the nature of these resources (max 150 words)** |
|  |

|  |
| --- |
| **8.2 Please summarise any NHS costs (excess treatment and NHS support costs) that the project will require (max 150 words)** |
|  |